Puma Biotechnology

PBYI65

High Value

$2.54arrow_drop_down0.78%-$0.02

High Value

Penny Stock

PBYI65

$2.54

arrow_drop_down0.78%-$0.02

High Value

Penny Stock

Performance History

Key Stats
Open	$2.53
Prev. Close	$2.56
EPS	0.19
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$122.61M

	LOW	HIGH
Day Range	2.50	2.59
52 Week Range	2.13	7.73

Ratios

Revenue	-


Earnings Growth %	-


EPS	0.19

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Puma Biotechnology (PBYI)

Puma Biotechnology Inc (PBYI) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. Founded in 2010, the company is based in Los Angeles, California. Puma Biotechnology's primary product is Nerlynx (neratinib), which is an orally administered tyrosine kinase inhibitor. The drug is approved for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Nerlynx is designed to inhibit the growth of tumor cells that overexpress the HER2 protein.

The stock price history of Puma Biotechnology Inc has exhibited volatility over the years. From its initial public offering (IPO) in 2012, the stock experienced significant ups and downs. Investors should carefully analyze the company's financial performance and future prospects before making any investment decisions. Puma Biotechnology Inc's market cap is an important metric to consider, as it represents the total value of a company's outstanding shares of stock. The market cap of Puma Biotechnology Inc can fluctuate based on various factors, including market conditions and investor sentiment.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Alan H. Auerbach
Headquarters: Los Angeles
Employees: 192
Exchange: NASDAQ

Keep an eye on Puma Biotechnology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Puma Biotechnology 's (PBYI) price per share?

The current price per share for Puma Biotechnology (PBYI) is $2.54. The stock has seen a price change of -$0.02 recently, indicating a -0.78% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Puma Biotechnology (PBYI)?

For Puma Biotechnology (PBYI), the 52-week high is $7.73, which is 204.33% from the current price. The 52-week low is $2.13, the current price is 19.25% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Puma Biotechnology (PBYI) a growth stock?

Puma Biotechnology (PBYI) has shown an average price growth of 0.41% over the past three years. It has received a score of 55 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Puma Biotechnology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Puma Biotechnology (PBYI) stock price performance year to date (YTD)?

As of the latest data, Puma Biotechnology (PBYI) has a year-to-date price change of -43.87%. Over the past month, the stock has experienced a price change of -10.25%. Over the last three months, the change has been -14.77%. Over the past six months, the figure is -40.93%. Looking at a longer horizon, the five-year price change stands at -77.26%.

help

Is Puma Biotechnology (PBYI) a profitable company?

Puma Biotechnology (PBYI) has a net income of $21.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 73.4% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.63% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 3.35%, providing insight into the company's sales performance and growth. The gross profit is $172.96M. Operating income is noted at $33.26M. Furthermore, the EBITDA is $35.69M.

help

What is the market capitalization of Puma Biotechnology (PBYI)?

Puma Biotechnology (PBYI) has a market capitalization of $122.62M. The average daily trading volume is 275.89K, indicating the stock's liquidity and investor engagement.